BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

GHRS

GH Research PLC NASDAQ Listed Jun 25, 2021
Healthcare ·Biotechnology ·IE · ghres.com
$21.00
Mkt Cap $1.3B
52w Low $9.46 75.9% of range 52w High $24.66
50d MA $16.55 200d MA $14.68
P/E (TTM) -26.2x
EV/EBITDA -8.8x
P/B 4.5x
Debt/Equity 0.0x
ROE
P/FCF -17.8x
RSI (14)
ATR (14)
Beta 1.00
50d MA $16.55
200d MA $14.68
Avg Volume 222.8K
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
SIC Code
2834
CIK (SEC)
Phone
353 1 437 8443
28 Baggot Street Lower · Dublin, L2 D02 NX43 · IE
Data updated apr 25, 2026 11:22am · Source: massive.com